An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
Status:
Withdrawn
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-study with a 26 week open label treatment period followed by an optional 26
week open label extension. The total treatment period will be 52 weeks.